OncoMatch/Clinical Trials/NCT05921253
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
Is NCT05921253 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including PARASYM neuromodulation device and PARASYM neuromodulation device for breast cancer.
Treatment: PARASYM neuromodulation device · PARASYM neuromodulation device — This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Demographics
Prior therapy
Must have received: anthracycline
have received anthracycline-based therapy for breast cancer or lymphoma within the last 30 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stephenson Cancer Center · Oklahoma City, Oklahoma
- Stephenson Cancer Center- Tulsa · Tulsa, Oklahoma
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05921253 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anthracycline.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages